Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Change in Receivables (2020 - 2025)

NeuroPace has reported Change in Receivables over the past 6 years, most recently at -$257000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$257000.0 for Q4 2025, down 119.94% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 241.42% YoY), and the annual figure for FY2025 was $1.8 million, up 241.42%.
  • Change in Receivables for Q4 2025 was -$257000.0 at NeuroPace, down from $1.4 million in the prior quarter.
  • Over the last five years, Change in Receivables for NPCE hit a ceiling of $2.6 million in Q1 2025 and a floor of -$1.9 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $62000.0 (2021), compared with a mean of $315150.0.
  • Biggest five-year swings in Change in Receivables: soared 1115.46% in 2022 and later crashed 383.55% in 2025.
  • NeuroPace's Change in Receivables stood at $480000.0 in 2021, then crashed by 181.67% to -$392000.0 in 2022, then skyrocketed by 368.37% to $1.1 million in 2023, then increased by 22.53% to $1.3 million in 2024, then plummeted by 119.94% to -$257000.0 in 2025.
  • The last three reported values for Change in Receivables were -$257000.0 (Q4 2025), $1.4 million (Q3 2025), and -$1.9 million (Q2 2025) per Business Quant data.